Remicade (infliximab), a new biotech drug for Crohn's disease

Centocor will market Remicade (infliximab), a new biotech drug for Crohn's disease.

It's a monoclonal antibody that neutralizes the activity of tumor necrosis factor...a protein that promotes inflammation.

Remicade is also being tested for other inflammatory conditions such as rheumatoid arthritis.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote